BOCA RATON, Fla. — Massive Bio and Just Worldwide have formed a strategic partnership aimed at connecting more cancer patients with clinical trial opportunities through patient communities, advocacy groups and AI-driven trial matching.
Massive Bio, an AI-driven clinical trial matching company focused on oncology, and Just Worldwide, a healthcare fieldwork and market research provider, said the partnership is designed to raise awareness of available cancer studies, onboard interested patients and support the collection of medical records for eligibility review.
Under the agreement, Just Worldwide will use its patient engagement network to reach patients, advocacy groups and patient organizations within the scope of selected clinical trials. Massive Bio’s clinical team will then use its SYNERGY-AI platform to assess patients and identify relevant trial matches.
Access to clinical trials remains a major challenge in oncology, particularly for patients treated outside major academic medical centers or those who rely on community organizations and advocacy networks for information. The companies said the partnership is intended to create a pathway from community-level outreach to trial matching and connection with study coordinators.
Massive Bio said its SYNERGY-AI platform has generated more than 17,000 oncologist-confirmed clinical trial matches across more than 17 countries.
“As oncologists, we know that the right clinical trial can be a turning point for a patient – but only if they know it exists. Just Worldwide’s ability to engage patients and advocacy communities at scale, combined with Massive Bio’s AI matching engine, creates a system where the right information finds the right patient at exactly the right moment in their journey,” said Arturo Loaiza-Bonilla, MD, Co-Founder & Chief Medical AI Officer, Massive Bio.
Just Worldwide will conduct outreach through its marketing and engagement channels, guide interested patients through a structured intake process and coordinate medical record collection. Massive Bio’s platform will then help identify the most relevant trial opportunities and connect patients with appropriate study coordinators.
The companies said the model is intended to keep patients informed and supported throughout the process, from initial awareness to submission of medical records and eligibility assessment.
Just Worldwide said it has a multicultural team operating across North America, Europe and Asia and is a long-term member of BHBIA and EphMRA. The company said it follows international and local research and patient engagement guidelines.
“Clinical trial underenrollment is not just a patient access problem – it is a structural inefficiency that costs the industry time, resources, and ultimately, outcomes. This partnership addresses that gap by channeling patients through trusted community networks directly into our matching infrastructure. The model is scalable, compliant, and built to deliver measurable impact on enrollment rates,” said Toygun Rauf Onaran, Chief Financial Officer, Massive Bio.
“At Just Worldwide, we have always started with listening to patients, including those who might be underrepresented in research. This partnership with Massive Bio allows us to extend that commitment beyond market research – by helping connect patients we engage with to clinical trial opportunities, we are taking another step toward the ultimate aim of improving patient outcomes,” said Dan Buckley, Field Director, Just Worldwide.
